Stocks and Investing
Stocks and Investing
Tue, May 1, 2012
[ 06:22 AM ] - WOPRAI
[ 06:22 AM ] - WOPRAI
[ 06:22 AM ] - WOPRAI
[ 06:22 AM ] - WOPRAI
[ 06:21 AM ] - WOPRAI
[ 06:21 AM ] - WOPRAI
[ 06:21 AM ] - WOPRAI
[ 06:21 AM ] - WOPRAI
[ 06:20 AM ] - WOPRAI
[ 06:01 AM ] - Market Wire
[ 05:40 AM ] - WOPRAI
[ 05:40 AM ] - WOPRAI
[ 05:40 AM ] - WOPRAI
[ 05:40 AM ] - WOPRAI
[ 05:30 AM ] - Market Wire
[ 05:00 AM ] - Market Wire
[ 05:00 AM ] - Market Wire
[ 04:00 AM ] - Market Wire
[ 01:56 AM ] - Market Wire
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Jay Olson Maintained (BIIB) at Buy with Increased Target to $139 on, May 1st, 2012
Jay Olson of Oppenheimer, Maintained "Biogen Inc." (BIIB) at Buy with Increased Target from $136 to $139 on, May 1st, 2012.
Jay has made no other calls on BIIB in the last 4 months.
There is 1 other peer that has a rating on BIIB. Out of the 1 peers that are also analyzing BIIB, 0 agree with Jay's Rating of Hold.
This is the rating of the analyst that currently disagrees with Jay
- Matthew Harrison of "Morgan Stanley" Initiated at Buy and Held Target at $140 on, Friday, February 10th, 2012